Navigation Links
Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Date:5/3/2012

. In keeping with the company commitment to do the most good for the most people, Boehringer Ingelheim works hard to ensure its medicines are accessible to everyone who needs them, including senior citizens and families on limited incomes. The Boehringer Ingelheim Cares Foundation Patient Assistance Programs (BI-PAP) make Boehringer Ingelheim medicines available free of charge to patients who are without pharmaceutical insurance coverage, and who meet certain household income levels.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- Huntington Memorial Hospital is the first facility in ... replacement (TAVR), a minimally invasive replacement of heart valves. ... replace an aortic valve without a chest incision or ... The procedure is performed by a dedicated Huntington Hospital ... , MD, interventional cardiologist and Robbin Cohen , ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
(Date:3/26/2015)... According to a new market research report ... Cryoablation, Others), Department (Interventional Radiology, Surgery, Oncology), Application (Liver ... Forecasts to 2019", published by MarketsandMarkets, the Tumor Ablation ... at a CAGR of 11.50% by 2019. ... through 195 pages and in-depth TOC on "Tumor Ablation ...
Breaking Medicine Technology:Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4
... that it will report its 2010 year-end earnings on Thursday, April ... an analyst and investor call at 9:00 AM EDT live via ... in the conference call within the U.S. and Canada, dial (866) ... (708) 290-1340. The conference ID is 58484489. ...
... Boston Scientific Corporation (NYSE: BSX ... (FDA) approval and launch of the ION™ Paclitaxel-Eluting ... drug-eluting stent technology.  The ION Stent System incorporates ... for coronary stenting and intended to improve the ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 2Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 3Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 4Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 5
(Date:3/28/2015)... LTW Cyber is an innovation hub for technology ... of addressing the needs of the global market for ... to grow while seeking collaborative opportunities with the other ... in LTW Cyber focus on secure application security, grounded ... and analyzing open source. As the hub matures, ...
(Date:3/27/2015)... March 27, 2015 The federal court ... allege the statin medication increases the risk that a ... Inc.’s Motion to Dismiss four individual cases that had ... Management Order issued in the U.S. District Court, District ... that the dismissals were warranted because the plaintiffs in ...
(Date:3/27/2015)... California (PRWEB) March 27, 2015 ... Entertainment’s EcoLuxe Lounge in the Stardust Penthouse on ... Debbie Durkin, Los Angeles’ leading sustainable product TV ... behind this unforgettable day-long event, which featured some ... and ecologically sound products and services. , “We ...
(Date:3/27/2015)... According to a recently published report series ... screw market in Europe is in decline due to ... segment. Price decreases are being seen across the entire ... the total European trauma device market, continued pricing pressure ... year after year. , “Such price drops are ...
(Date:3/27/2015)... According to Health Day , on March 6th, ... (NAS) are causing alarm for Florida officials. Infants born ... a month of their lives- and can experience seizures, ... condition is precipitated by drug use during pregnancy. Unfortunately, ... medically assisted drug treatment) will also inflict NAS on ...
Breaking Medicine News(10 mins):Health News:Canadian Cybersecurity Ventures Globalize as a Collective 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2
... , MONDAY, March 7 (HealthDay News) -- Sleep tight, but ... message of a new survey that suggests many Americans might ... bedtime in front of the electronic glow of a television, ... exposure to bright light before bed disrupts sleep. But some ...
... , MONDAY, March 7 (HealthDay News) -- Genetics ... -- where fear and stress are a fact of daily ... decline, new research warns. The culprit is a specific ... that while this gene is known to play a key ...
... , MONDAY, March 7 (HealthDay News) -- Young adults ... less likely to achieve the same level of education ... Improved medical care over the past 40 years has ... surviving into adulthood. However, they carry the burden of ...
... less treatment in the American health care system than their ... dose of empathy helps close racial gaps in pain treatment. ... ease the pain of members of their own race in ... at the University of Wisconsin-Madison. "I want to be ...
... identified a critical part of the process by which ... childhood infections, respiratory syncytial virus, causes disease. ... for RSV, which in 2005 was estimated to have ... among children under five worldwide. By analyzing samples ...
... tumor growth, and naturally mounts an anti-cancer defense. Dendritic ... present them to T cells, and those "primed" T ... cells. In recent years, researchers have attempted to capitalize ... namely, by generating a pool of tumor antigen-pulsed DCs ...
Cached Medicine News:Health News:Using Electronics Before Bed May Hamper Sleep 2Health News:Using Electronics Before Bed May Hamper Sleep 3Health News:Mix of Genetics and Stress Can Impair Mental Abilities 2Health News:Surviving Serious Childhood Illness Takes Toll Later: Study 2Health News:Surviving Serious Childhood Illness Takes Toll Later: Study 3Health News:New perspective diminishes racial bias in pain treatment 2Health News:Scientists find key mechanism of childhood respiratory disease 2Health News:Scientists find key mechanism of childhood respiratory disease 3
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
Medicine Products: